

# Luca Gianni

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3531751/luca-gianni-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148  
papers

27,795  
citations

61  
h-index

161  
g-index

161  
ext. papers

32,554  
ext. citations

9  
avg. IF

6.68  
L-index

#	Paper	IF	Citations
148	Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1659-72	59.2	3921
147	Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. <i>Pharmacological Reviews</i> , <b>2004</b> , 56, 185-229	22.5	2619
146	Trastuzumab emtansine for HER2-positive advanced breast cancer. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 1783-91	59.2	2378
145	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , <b>2014</b> , 384, 164-72	40	2177
144	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 25-32	21.7	1438
143	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 674-690	19.4	1246
142	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. <i>Lancet, The</i> , <b>2010</b> , 375, 377-84	40	864
141	Treatment of HER2-positive breast cancer: current status and future perspectives. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 9, 16-32	19.4	606
140	Triple-negative breast cancer: disease entity or title of convenience?. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 683-92	19.4	588
139	Triple-negative breast cancer: an unmet medical need. <i>Oncologist</i> , <b>2011</b> , 16 Suppl 1, 1-11	5.7	542
138	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 236-44	21.7	500
137	Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1138-44	2.2	496
136	11 years follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. <i>Lancet, The</i> , <b>2017</b> , 389, 1195-1205	40	486
135	Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7265-77	2.7	461
134	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 27-39	21.7	413
133	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 791-800	21.7	408
132	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. <i>Lancet, The</i> , <b>2013</b> , 382, 1021-8	40	377

131	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 580-91	21.7	359
130	HER2-positive breast cancer. <i>Lancet, The</i> , <b>2017</b> , 389, 2415-2429	4.0	351
129	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 640-7	21.7	313
128	Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 732-742	21.7	289
127	Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 814-9	2.2	287
126	International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2600-8	2.2	276
125	Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. <i>Biochemistry</i> , <b>1982</b> , 21, 1707-12	3.2	219
124	AVAREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1719-25	2.2	211
123	30 years follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. <i>BMJ, The</i> , <b>2005</b> , 330, 217	5.9	195
122	Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1594-600	2.2	189
121	The immune system and response to HER2-targeted treatment in breast cancer. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e58-68	21.7	171
120	Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2159-65	2.2	164
119	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4316-23	2.2	163
118	Oxidative destruction of DNA by the adriamycin-iron complex. <i>Biochemistry</i> , <b>1984</b> , 23, 928-36	3.2	155
117	Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2474-81	2.2	152
116	Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 1867-74	2.2	148
115	Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 37-43	2.2	148
114	Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 511-21	12.9	143

113	Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1131-7	2.2	135
112	Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 8715-21	12.9	135
111	Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 329-35	2.2	133
110	Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 447-55	4.4	128
109	Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 510-520	21.7	123
108	Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 1746-50	7.5	121
107	Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. <i>FEBS Letters</i> , <b>1984</b> , 172, 226-30	3.8	119
106	Mechanism-based pharmacokinetic model for paclitaxel. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 4065-73	2.2	118
105	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1529-1541	59.2	108
104	Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1614-20	2.2	102
103	Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 413-423	18.8	98
102	Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. <i>Cardiovascular Toxicology</i> , <b>2007</b> , 7, 67-71	3.4	94
101	Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Presta) is independent of EGFR expression level. <i>Journal of Cellular Physiology</i> , <b>2004</b> , 198, 259-68	7	91
100	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 249-256	21.7	89
99	Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 702-10	6.1	83
98	Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1685-93	2.2	81
97	Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1003-1003	2.2	81
96	Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 10990-1001	5.4	75

95	Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 302-308	13.4	74
94	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1818-1831	8.9	73
93	Role of anthracyclines in the treatment of early breast cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4798-808	2.2	71
92	Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. <i>Nature Clinical Practice Oncology</i> , <b>2009</b> , 6, 93-104		68
91	Targeting TRAIL agonistic receptors for cancer therapy. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 2313-7	12.9	64
90	Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1437-44	2.2	63
89	Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. <i>Annals of Oncology</i> , <b>1991</b> , 2 Suppl 1, 9-16	10.3	59
88	Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> ,	19.4	56
87	International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , <b>2011</b> , 2011, 147-51	4.8	55
86	Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 318, 424-33	4.7	53
85	Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. <i>Breast Cancer Research</i> , <b>2017</b> , 19, 16	8.3	52
84	Differences in O <sub>2</sub> reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>1986</b> , 884, 326-36	4	52
83	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2 Breast Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 3280-3292	10.1	51
82	Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. <i>Cancer Research</i> , <b>2010</b> , 70, 8852-62	10.1	49
81	Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1136-42	2.2	46
80	Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients. <i>Anti-Cancer Drugs</i> , <b>2000</b> , 11, 331-7	2.4	44
79	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 337-45	12.9	43
78	Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4554-61	2.2	43

77	Future options with trastuzumab for primary systemic and adjuvant therapy. <i>Seminars in Oncology</i> , <b>2004</b> , 31, 51-7	5.5	42
76	Hallmarks of triple negative breast cancer emerging at last?. <i>Cell Research</i> , <b>2014</b> , 24, 904-5	24.7	39
75	Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. <i>Breast Cancer Research</i> , <b>2014</b> , 16, R50	8.3	37
74	Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 5944-51	12.9	37
73	Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 171-8	7.5	35
72	Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2222-31	2.2	35
71	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. <i>Breast Cancer Research</i> , <b>2013</b> , 15, R86	8.3	33
70	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , <b>2018</b> , 102, 95-102	7.5	32
69	Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 691-697	18.8	31
68	Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2007</b> , 320, 790-800	4.7	31
67	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA1-LBA1	2.2	31
66	Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1059-1059	2.2	30
65	Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1954-60	2.2	28
64	Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. <i>BJU International</i> , <b>2009</b> , 104, 340-6	5.6	26
63	Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 290-6	8.7	25
62	Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 505-505	2.2	25
61	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , <i>The</i> , <b>2021</b> , 22, 1139-1150	21.7	24
60	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , <b>2017</b> , 83, 106-115	7.5	21

59	Anthracycline cardiotoxicity. <i>Topics in Current Chemistry</i> , <b>2008</b> , 283, 21-44		21
58	The future of targeted therapy: combining novel agents. <i>Oncology</i> , <b>2002</b> , 63 Suppl 1, 47-56	3.6	21
57	Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2158-65	2.2	20
56	Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. <i>Breast</i> , <b>2012</b> , 21, 507-13	3.6	20
55	Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy. <i>Investigational New Drugs</i> , <b>2001</b> , 19, 179-96	4.3	20
54	Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer. <i>Nature Clinical Practice Oncology</i> , <b>2004</b> , 1, 44-50		19
53	Cardiotoxic effects of anthracycline-taxane combinations. <i>Expert Opinion on Drug Safety</i> , <b>2003</b> , 2, 59-71	4.1	19
52	Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 1188-96	4.3	16
51	Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1236-43	4.3	15
50	The "other" signaling of trastuzumab: antibodies are immunocompetent drugs. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1778-80	2.2	15
49	Adjuvant and neoadjuvant treatment of breast cancer. <i>Seminars in Oncology</i> , <b>2001</b> , 28, 13-29	5.5	14
48	Monoclonal antibodies against doxorubicin. <i>International Journal of Cancer</i> , <b>1988</b> , 42, 798-802	7.5	14
47	Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 505-505	2.2	14
46	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA1-LBA1	2.2	13
45	Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014). <i>Ecancermedicalscience</i> , <b>2014</b> , 8, 433	2.7	11
44	Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. <i>ESMO Open</i> , <b>2018</b> , 3, e000303	6	9
43	Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 503-503	2.2	9
42	Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123194	3.7	9

41	Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 679-697	8.7	8
40	Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples. <i>PLoS ONE</i> , <b>2014</b> , 9, e86511	3.7	8
39	Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 515-515	2.2	7
38	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 155, 127-32	4.4	6
37	Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 512-512	2.2	6
36	Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 641-650	3.5	5
35	A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer. <i>Clinical Breast Cancer</i> , <b>2012</b> , 12, 167-74	3	5
34	Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors <b>2008</b> ,		5
33	Never use anthracyclines with trastuzumab: it is time to reconsider the taboo. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 117, 599-601	4.4	4
32	Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study. <i>Clinical Breast Cancer</i> , <b>2006</b> , 7, 321-5	3	4
31	Learning from CI-941 about pharmacokinetically guided dose escalation. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 1302-4	7.5	3
30	Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimen. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1990</b> , 13, 199-203	2.7	3
29	Four-drug sequential regimen in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>1987</b> , 10, 151-7	4.4	3
28	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2100896	2.2	3
27	Is there room for another HER2-targeting drug?. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 847-849	21.7	3
26	Pathological complete response in breast cancer--authorsPreply. <i>Lancet, The</i> , <b>2015</b> , 385, 114-5	4.0	2
25	Surrogate markers for targeted therapy-based treatment activity and efficacy. <i>Journal of the National Cancer Institute Monographs</i> , <b>2011</b> , 2011, 91-4	4.8	2
24	The cost of life: should it matter to doctors?. <i>Annals of Oncology</i> , <b>2006</b> , 17, 357-8	10.3	2



23	New active drugs in the treatment of lymphomas. <i>Current Opinion in Oncology</i> , <b>1994</b> , 6, 480-8	4.2	2
22	Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 532-532	2.2	2
21	Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 527-527	2.2	2
20	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1014-1014	2.2	2
19	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5096-5108	12.9	2
18	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 99, 102229	14.4	2
17	BOLERO-3 results: pharmacological activity or pharmacokinetic effect?--authorsPreply. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e304-5	21.7	1
16	Reply to S.M. Ali et al. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e274-e275	2.2	1
15	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 827625	5.3	1
14	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer.. <i>Npj Breast Cancer</i> , <b>2022</b> , 8, 1	7.8	0
13	Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 117-121	3.3	0
12	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. <i>Anticancer Research</i> , <b>2019</b> , 39, 797-802	2.3	
11	State of the art of adjuvant therapy. <i>European Journal of Cancer, Supplement</i> , <b>2008</b> , 6, 27-30	1.6	
10	The Choice of the Correct Imaging Modality in Breast Cancer Management <b>2008</b> , 281-292		
9	Demethylating agents to upregulate HLAs and antigen presenting machinery (APM) related genes in HER2+ breast cancer (BC) cell lines.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e13012-e13012	2.2	
8	The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS2596-TPS2596	2.2	
7	An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 530-530	2.2	
6	Strategies for clinical development of monoclonal antibodies beyond first-in-man trials: Tested doses and rationale for dose selection.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3040-3040	2.2	

5 Introduction and background biology **2016**, 1-13

4 Cardiovascular Toxicity of Antitumor Drugs: Translating Molecular Mechanisms into Clinical Facts **2016**, 223-256

3 Pertuzumab as HER-2 Dimerisation Inhibitor for the Treatment of Breast and Other Cancers **2011**, 73-90

2 Introduction and Background Biology **2013**, 1-12

1 Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO).. *Journal of Clinical Oncology*, **2013**, 31, 537-537 2.2